Cargando…
Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1(+) T-cells and acts on antigen-specific stem-like PD-1(+) TCF-1(+) CD8(+) T-cells expanding and differentiating them towards better effectors resulting in sup...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072055/ https://www.ncbi.nlm.nih.gov/pubmed/37025392 http://dx.doi.org/10.1080/2162402X.2023.2197360 |